EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Sept. 12, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”) under the Company’s…

Read More

Press Releases

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Jan. 09, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received an additional development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”) under the…

Read More

Press Releases

EyeGate Receives Approval from FDA to Initiate PRK Pivotal Study

WALTHAM, Mass., June 3, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”) announced today it has received approval from the U.S. Food and Drug Administration (“FDA”) to initiate its photorefractive keratectomy (“PRK”) pivotal study. The FDA has determined that EyeGate provided sufficient data to support initiation of the clinical study and…

Read More

Press Releases

EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for Post-operative Ocular Inflammation and Pain in Ocular Surgery Patients

WALTHAM, Mass., May 22, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced that it has received its first development milestone from a subsidiary of Valeant Pharmaceuticals International, Inc. (“Valeant”) under the…

Read More

Press Releases

EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients

Company Plans to Initiate Randomized, Double-masked, Placebo-Controlled Study in First Half of 2017 WALTHAM, Mass., Dec. 05, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced promising data from the third…

Read More

Press Releases

Eyegate Pharmaceuticals To Present At The Noble Financial Capital Markets’ 12th Annual Investor Conference

WALTHAM, Mass., January 14, 2016 — Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG, EYEGW) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble…

Read More

Press Releases

EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

WALTHAM, Mass., January 24, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, today announced that Stephen From, President & Chief Executive Officer of EyeGate, is scheduled to present at the Noble Financial…

Read More

Press Releases

EyeGate Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

WALTHAM, MA., August 3, 2018 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three month period ended June 30, 2018, and provided an update on recent corporate and operational…

Read More

Press Releases

EyeGate Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 02, 2016 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2016, and provided an update on recent corporate and operational…

Read More

Press Releases

EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

WALTHAM, Mass., Nov. 14, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2017, and provided an update on recent corporate and operational activities.…

Read More

Press Releases